Literature DB >> 20160348

Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting TrkC-induced apoptosis.

Jimena Bouzas-Rodriguez1, Jorge Ruben Cabrera, Céline Delloye-Bourgeois, Gabriel Ichim, Jean-Guy Delcros, Marie-Anne Raquin, Raphaël Rousseau, Valérie Combaret, Jean Bénard, Servane Tauszig-Delamasure, Patrick Mehlen.   

Abstract

Tropomyosin-related kinase receptor C (TrkC) is a neurotrophin receptor with tyrosine kinase activity that was expected to be oncogenic. However, it has several characteristics of a tumor suppressor: its expression in tumors has often been associated with good prognosis; and it was recently demonstrated to be a dependence receptor, transducing different positive signals in the presence of ligand but inducing apoptosis in the absence of ligand. Here we show that the TrkC ligand neurotrophin-3 (NT-3) is upregulated in a large fraction of aggressive human neuroblastomas (NBs) and that it blocks TrkC-induced apoptosis of human NB cell lines, consistent with the idea that TrkC is a dependence receptor. Functionally, both siRNA knockdown of NT-3 expression and incubation with a TrkC-specific blocking antibody triggered apoptosis in human NB cell lines. Importantly, disruption of the NT-3 autocrine loop in malignant human neuroblasts triggered in vitro NB cell death and inhibited tumor growth and metastasis in both a chick and a mouse xenograft model. Thus, we believe that our data suggest that NT-3/TrkC disruption is a putative alternative targeted therapeutic strategy for the treatment of NB.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20160348      PMCID: PMC2827960          DOI: 10.1172/JCI41013

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  52 in total

Review 1.  Neurotrophins: roles in neuronal development and function.

Authors:  E J Huang; L F Reichardt
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

2.  Rational basis for Trk inhibition therapy for prostate cancer.

Authors:  A T Weeraratna; J T Arnold; D J George; A DeMarzo; J T Isaacs
Journal:  Prostate       Date:  2000-10-01       Impact factor: 4.104

3.  Autocrine expression of neurotrophins and their receptors in prostate cancer.

Authors:  F Satoh; H Mimata; T Nomura; Y Fujita; T Shin; S Sakamoto; Y Hamada; Y Nomura
Journal:  Int J Urol       Date:  2001-07       Impact factor: 3.369

4.  Expression of neurotrophins and their receptors in pigment cell lesions of the skin.

Authors:  P F Innominato; L Libbrecht; J J van den Oord
Journal:  J Pathol       Date:  2001-05       Impact factor: 7.996

Review 5.  Trk receptor tyrosine kinases: a bridge between cancer and neural development.

Authors:  A Nakagawara
Journal:  Cancer Lett       Date:  2001-08-28       Impact factor: 8.679

6.  Neurotrophins and neurotrophin receptors in human lung cancer.

Authors:  A Ricci; S Greco; S Mariotta; L Felici; E Bronzetti; A Cavazzana; G Cardillo; F Amenta; A Bisetti; G Barbolini
Journal:  Am J Respir Cell Mol Biol       Date:  2001-10       Impact factor: 6.914

7.  Expression of Trk tyrosine kinase receptor is a biologic marker for cell proliferation and perineural invasion of human pancreatic ductal adenocarcinoma.

Authors:  Y Sakamoto; Y Kitajima; G Edakuni; E Sasatomi; M Mori; K Kitahara; K Miyazaki
Journal:  Oncol Rep       Date:  2001 May-Jun       Impact factor: 3.906

8.  Implication of Bcl-2 and Caspase-3 in age-related Purkinje cell death in murine organotypic culture: an in vitro model to study apoptosis.

Authors:  A M Ghoumari; R Wehrlé; O Bernard; C Sotelo; I Dusart
Journal:  Eur J Neurosci       Date:  2000-08       Impact factor: 3.386

9.  TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors.

Authors:  M A Grotzer; A J Janss; K Fung; J A Biegel; L N Sutton; L B Rorke; H Zhao; A Cnaan; P C Phillips; V M Lee; J Q Trojanowski
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

10.  Netrin-1 acts as a survival factor for aggressive neuroblastoma.

Authors:  Céline Delloye-Bourgeois; Julien Fitamant; Andrea Paradisi; David Cappellen; Setha Douc-Rasy; Marie-Anne Raquin; Dwayne Stupack; Akira Nakagawara; Raphaël Rousseau; Valérie Combaret; Alain Puisieux; Dominique Valteau-Couanet; Jean Bénard; Agnès Bernet; Patrick Mehlen
Journal:  J Exp Med       Date:  2009-04-06       Impact factor: 14.307

View more
  26 in total

1.  The Ectodysplasin receptor EDAR acts as a tumor suppressor in melanoma by conditionally inducing cell death.

Authors:  Jonathan Vial; Amélie Royet; Philippe Cassier; Antonin Tortereau; Sarah Dinvaut; Denis Maillet; Lise Gratadou-Hupon; Marion Creveaux; Alexa Sadier; Garance Tondeur; Sophie Léon; Lauriane Depaepe; Sophie Pantalacci; Arnaud de la Fouchardière; Olivier Micheau; Stéphane Dalle; Vincent Laudet; Patrick Mehlen; Marie Castets
Journal:  Cell Death Differ       Date:  2018-05-31       Impact factor: 15.828

2.  Neurotrophins in healthy and diseased skin.

Authors:  Francesca Truzzi; Alessandra Marconi; Carlo Pincelli
Journal:  Dermatoendocrinol       Date:  2011-01

Review 3.  Perineural growth in head and neck squamous cell carcinoma: a review.

Authors:  Joseph Roh; Thomas Muelleman; Ossama Tawfik; Sufi M Thomas
Journal:  Oral Oncol       Date:  2014-10-25       Impact factor: 5.337

4.  Context is everything for dependence receptors in colorectal cancer.

Authors:  William M Grady
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-08       Impact factor: 11.205

5.  Methylation and expression patterns of tropomyosin-related kinase genes in different grades of glioma.

Authors:  Mahalakshmi Palani; R Arunkumar; Arrambakam Janardhanam Vanisree
Journal:  Neuromolecular Med       Date:  2014-05-20       Impact factor: 3.843

6.  Detection of aberrant methylated SEPT9 and NTRK3 genes in sporadic colorectal cancer patients as a potential diagnostic biomarker.

Authors:  Shahin Behrouz Sharif; Shahriar Hashemzadeh; Reza Mousavi Ardehaie; Amirtaher Eftekharsadat; Mortaza Ghojazadeh; Amir Hossein Mehrtash; Mehrdad Asghari Estiar; Ladan Teimoori-Toolabi; Ebrahim Sakhinia
Journal:  Oncol Lett       Date:  2016-10-31       Impact factor: 2.967

7.  TrkC expression predicts favorable clinical outcome in invasive ductal carcinoma of breast independent of NT-3 expression.

Authors:  Wei Zhang; Zhi-Chun Lin; Tong-Xian Zhang; Shan Liu; Xia Liu; Jun-Jun Liu; Yun Niu
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

8.  Blocking SHH/Patched Interaction Triggers Tumor Growth Inhibition through Patched-Induced Apoptosis.

Authors:  Patrick Mehlen; Joanna Fombonne; Pierre-Antoine Bissey; Pauline Mathot; Catherine Guix; Mélissa Jasmin; Isabelle Goddard; Clélia Costechareyre; Nicolas Gadot; Jean-Guy Delcros; Sachitanand M Mali; Rudi Fasan; André-Patrick Arrigo; Robert Dante; Gabriel Ichim
Journal:  Cancer Res       Date:  2020-02-14       Impact factor: 12.701

9.  Trks are novel oncogenes involved in the induction of neovascularization, tumor progression, and nodal metastasis in oral squamous cell carcinoma.

Authors:  Tomonori Sasahira; Nobuhiro Ueda; Kazuhiko Yamamoto; Ujjal K Bhawal; Miyako Kurihara; Tadaaki Kirita; Hiroki Kuniyasu
Journal:  Clin Exp Metastasis       Date:  2012-08-12       Impact factor: 5.150

10.  Dependence receptor TrkC is a putative colon cancer tumor suppressor.

Authors:  Anne-Laure Genevois; Gabriel Ichim; Marie-May Coissieux; Marie-Pierre Lambert; Fabrice Lavial; David Goldschneider; Loraine Jarrosson-Wuilleme; Florian Lepinasse; Géraldine Gouysse; Zdenko Herceg; Jean-Yves Scoazec; Servane Tauszig-Delamasure; Patrick Mehlen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.